Allergan Aesthetics, an AbbVie company
Juvéderm Voluma XC
A hyaluronic acid filler formulated for deep structural augmentation in specific approved facial areas.
Hyaluronic acid dermal fillerReviewed 7/30/2026Source recorded
At a glance
| Primary purpose | Deep augmentation for age-related midface volume deficit, chin-profile improvement, and temple hollowing in adults over 21 under the current US labelling. |
|---|---|
| Mechanism | A 20 mg/mL cross-linked hyaluronic acid gel with 0.3% lidocaine is implanted in product-specific deep tissue planes to add volume and contour. |
| When results appear | Volume change is immediate; touch-up assessment in pivotal studies occurred after early swelling, commonly at weeks rather than the same day. |
| Typical sessions | One initial treatment with possible touch-up according to the labelled area and study protocol. |
| Downtime | Injection-site responses are common and may last days to weeks. |
| Longevity | Cheek clinical-study benefit was evaluated through up to 24 months; this is not a promise that every treatment or newly approved area lasts 24 months. |
| Reversibility | May often be reduced with off-label hyaluronidase, but complete or immediate reversal is not guaranteed. |
| Documented risks | Swelling, tenderness, firmness, lumps, bruising, redness, infection, inflammatory reactions, and rare intravascular injection with necrosis, visual impairment, or stroke. |
| Most common disappointment | Using a structural cheek/chin/temple filler for a lip goal is an intended-area mismatch; one syringe may also be insufficient for bilateral structural correction. |
| Common marketing misconception | Voluma and Restylane Kysse are not like-for-like products merely because both are HA fillers. |
| What varies by provider | Area-specific plane, amount, facial proportions, injection technique, and vascular anatomy. |
| Skin-tone considerations | The US labelling reports study enrollment across Fitzpatrick skin types; this does not eliminate individual risk of bruising, inflammation, or pigment change. |
| When this treatment may not be appropriate | Not appropriate for lip augmentation under this profile or when filler contraindications, infection, severe allergy history, or a non-volume concern applies. |
| United States regulatory status | FDA-approved by PMA supplements for cheek augmentation for age-related midface volume deficit, chin augmentation, and temple hollowing in adults over 21. |
| Canadian regulatory status | Health Canada MDALL lists Juvéderm Voluma with lidocaine under active Class III medical-device licence 77899. |
| Evidence status | High for formulation, labelled areas, contraindications, adverse events, and pivotal-study follow-up; individual durability and required volume vary. |
Sources
- FDA PMA P110033/S070FDA PMA record · regulatory-primary · supports 2 profile fields
- Health Canada MDALL: Allergan Juvéderm licencesHealth Canada MDALL · regulatory-primary
- Juvéderm Voluma XC Instructions for Use, P110033/S070FDA-approved device labelling · regulatory-primary · supports 25 profile fields
- JUVÉDERM VOLUMA XC summary of safety and effectivenessregulator
Related comparisons
See average treatment prices near you
Enter a US ZIP code or Canadian postal code to check our stored estimate for the surrounding market.